HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Raises Price Target to $182
HC Wainwright & Co. analyst Michael King maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $171 to $182.
Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Nov. 3, 2021
Zoom Video (ZM)
Exact Sciences (EXAS)
Twilio (TWLO)
Robinhood (HOOD)
UIPath (PATH)
DraftKings (DKNG)
Intellia Therapeutics (NTLA)
Beam Therapeutics (BEAM)
Teladoc (TDOC)
NIU Technologies
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Cathie Wood’s ARK Invest Posts Fund Purchases For Friday, Oct. 29, 2021: NTLA, PACB, ACHR, MKFG, BLDE, FB, CDNA, DOC, EXAS, VERV, BEAM
Intellia Therapeutics (NTLA) - 34,200
Pacific Biosciences of California (PACB) - 119,183
Archer Aviation (ACHR) - 591,618
MarkForged Holding Corp (MKFG) - 76,612
Blade
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation For NTLA-2001, An Investigational CRISPR Therapy For The Treatment Of Transthyretin Amyloidosis
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S.
Intellia Therapeutics Shares Quiet As Traders Circulate Oct. 19-Dated AccessData.FDA.gov Listing For Orphan Drug Designation Of Co.’s Transtheyretin Amyloidosis Treatment
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=842521
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements In Its Broad Genome Editing Capabilities At The 2021 European Society Of Gene & Cell Therapy Annual Congress
First preclinical data demonstrating Intellia's allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments
Demonstrated lipid nanoparticle-based delivery as a more efficient
Cathie Wood’s ARK Invest Posts Fund Purchases For Tuesday, Oct. 12 2021: TDOC, CRSP, NTLA, SSYS, MKFG, BLDE, VLD, GENI, TWOU, CDNA, ARCT, SLGC, BEAM, QSI, DYNS
Teladoc Health (TDOC) - 198,681 Shares
CRISPR Therapeutics (CRSP) - 61,732
Intellia Therapeutics (NTLA) - 13,254
Stratasys (SSYS) - 26,989
Markforged (MKFG) - 179,691
Blade Air Mobility (BLDE) - 94,782
Velo3D
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.